Status: Recruiting
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.
Participants needed: 850
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Xuanwu Hospital, BeijingUpdated: Apr 9, 2026Locations: 1
Eligibility criteria
Age is ≥18 years. [+4]
Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhag... [+24]